Advancing Off-the-Shelf CRISPR CAR-T Therapies into the Community Setting with Caribou Biosciences' Rachel Haurwitz

We love to hear from our listeners. Send us a message. Welcome to episode 120 of Cell & Gene: The Podcast. Host Erin Harris is joined by Rachel Haurwitz, CEO of Caribou Biosciences, to discuss the company’s progress in developing CRISPR-edited, off-the-shelf CAR-T therapies for hematologic malignancies. Their conversation centers on Vispacell, Caribou’s allogeneic CD19 CAR-T for second-line large B-cell lymphoma. Haurwitz explains how Caribou has systematically optimized its allogeneic platform using clinical and translational data. They also cover pivotal Phase 3 trial planning, regulatory considerations, and what to expect next from Caribou’s broader pipeline, including its BCMA-targeted program in multiple myeloma.

You can listen to Advancing Off-the-Shelf CRISPR CAR-T Therapies into the Community Setting with Caribou Biosciences' Rachel Haurwitz online on Radio and Podcast. Open the player on this page to stream the available audio.

Advancing Off-the-Shelf CRISPR CAR-T Therapies into the Community Setting with Caribou Biosciences' Rachel Haurwitz is an episode from Cell & Gene: The Podcast by Erin Harris.

This episode is 19:32 long.

This episode was published on Jan 15, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Cell & Gene: The Podcast when more episodes are available from the podcast feed.